Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
NTO-1151 by Ology Bioservices for Recurrent Glioblastoma Multiforme (GBM): Likelihood of Approval
NTO-1151 is under clinical development by Ology Bioservices and currently in Phase I for Recurrent Glioblastoma Multiforme (GBM). According to...
NTO-1151 by Ology Bioservices for Neuroendocrine Tumors: Likelihood of Approval
NTO-1151 is under clinical development by Ology Bioservices and currently in Phase II for Neuroendocrine Tumors. According to GlobalData, Phase...
NanoDOX by Ology Bioservices for Wounds: Likelihood of Approval
NanoDOX is under clinical development by Ology Bioservices and currently in Phase II for Wounds. According to GlobalData, Phase II...